<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="149659">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01895088</url>
  </required_header>
  <id_info>
    <org_study_id>ACU-P12-020C</org_study_id>
    <nct_id>NCT01895088</nct_id>
  </id_info>
  <brief_title>A Continuation Study To Monitor The Long Term Safety Of Patients Completing Protocols ACU-P08-020/020A</brief_title>
  <acronym>020C</acronym>
  <official_title>A Continuation Study To Monitor The Long Term Safety Of The AcuFocus â„¢ ACI 7000PDT Patients Completing Protocols ACU-P08-020/020A</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AcuFocus, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AcuFocus, Inc.</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a 2 year follow up study to monitor the long term safety of the ACI 7000PDT in
      subjects who are still implanted with the ACI and have successfully completed the
      ACU-P08-020/020A studies.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a two year follow up study designed to monitor and obtain long-term safety data of
      the ACI 7000PDT in subjects who participated and successfully completed the ACU-P08-020/020A
      studies. Subjects must be able to provide voluntary informed consent, and must sign and be
      given a copy of the written Informed Consent form prior to participating. This continuation
      study follows subjects still implanted with the ACI and includes two visits, at 12-month
      intervals, after subjects have been exited (at Month 36) from the ACU-P08-020/020A studies.
      The first visit is at Month 48 following implantation followed by a final Month 60 visit.
      The study parameters being measured at these two visits include:

        -  Specular microscopy

        -  Slit lamp and fundus examination (ocular health)

        -  Corrected and uncorrected visual acuity

        -  Manifest mid-point refraction

        -  Corneal topography

        -  Dry eye assessment

        -  Mesopic and Photopic contrast sensitivity

        -  Adverse events and complications

      All sites participating in the ACU-P08-020/020A studies were invited to participate in the
      continuation study.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Anticipated">May 2015</completion_date>
  <primary_completion_date type="Anticipated">April 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Improvement in uncorrected near visual acuity</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Visual acuity testing will be performed using an Optec Vision Tester. Subject will be asked to identify letters in the vision tester chart. Each letter read correctly is scored as one point.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Presbyopia</condition>
  <arm_group>
    <arm_group_label>Patients previously impanted with 7000PDT</arm_group_label>
    <description>Patients previously implanted with AcuFocus Corneal Inlay 7000PDT in the ACU-P08-020/020A study</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>AcuFocus Corneal Inlay 7000PDT</intervention_name>
    <arm_group_label>Patients previously impanted with 7000PDT</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Potential participants must have completed the ACU-P08-020/020A study protocol.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must have completed participation in the ACU-P08-020/020A clinical trial.

          -  Patients must be able to provide voluntary informed consent, and must sign and be
             given a copy of the written Informed Consent form.

        Exclusion Criteria:

          -  Patients who did not complete ACU-P08-020/020A.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel Durrie, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Durrie Vision</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Chad Betts, M.D., R.Ph</last_name>
    <role>Principal Investigator</role>
    <affiliation>MacDonald Eye Associates</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Vance Thompson, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vance Thompson Vision</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jay Pepose, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pepose Vision Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kevin Waltz, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Eye Surgeons of Indiana</affiliation>
  </overall_official>
  <overall_official>
    <last_name>John Vukich, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Davis Duehr Dean</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Peter Hersh, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cornea and Laser Eye Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Thomas Tooma, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>NVision</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Colman Kraff, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kraff Eye Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Robert Maloney, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maloney Vision Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Scott MacRae, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Rochester Eye Institute - Strong Vision</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gary Foster, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Eye Center of Northern Colorado</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Phillip Hoopes, Sr., M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hoopes Vision</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>McDonald Eye Associates</name>
      <address>
        <city>Fayetteville</city>
        <state>Arkansas</state>
        <zip>72703</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maloney Vision</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NVision</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92660</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eye Center NOCO</name>
      <address>
        <city>Fort Collins</city>
        <state>Colorado</state>
        <zip>80525</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kraff Eye Institute</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60602</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eye Surgeons of Indiana</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46256</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Durrie Vision</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pepose Vision Institute</name>
      <address>
        <city>Chesterfield</city>
        <state>Missouri</state>
        <zip>63017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Cornea &amp; Laser Eye Institute, P.A</name>
      <address>
        <city>Teaneck</city>
        <state>New Jersey</state>
        <zip>07666</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Rochester Eye Institute - Strong Vision</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14618</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vance Thompson Vision</name>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <zip>57105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hoopes Vision</name>
      <address>
        <city>Sandy</city>
        <state>Utah</state>
        <zip>84070</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Davis Duehr Dean</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53715</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <lastchanged_date>July 5, 2013</lastchanged_date>
  <firstreceived_date>May 3, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>presbyopia</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Presbyopia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
